Clinical Trial Update: A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RL-007 for cognitive impairment associated with schizophrenia (CIAS) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Associated with Schizophrenia
• Schizophrenia

Drugs mentioned

• RL-007

Snippet

Sponsor: Recognify Life Sciences | Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment | Phase 2 | Status: COMPLETED